Isomorphic Labs and MSD form AI drug discovery partnership
Isomorphic Labs and MSD have formed a research collaboration to discover small-molecule therapeutic candidates aimed at an oncology target of strategic importance. The agreement combines Isomorphic Labs’ artificial intelligence drug design engine with MSD’s proprietary data and drug discovery expertise.
- Isomorphic Labs and MSD will discover small-molecule oncology candidates.
- Isomorphic Labs will use its IsoDDE engine for computational predictions and molecular designs.
- MSD will handle preclinical and clinical development, manufacturing and commercialization.
- Isomorphic Labs will receive an upfront payment, milestone payments and tiered royalties.
- The agreement does not disclose the target, payment values or royalty rates.
AI design and pharmaceutical data
Under the collaboration, Isomorphic Labs will conduct in silico predictions and provide molecular designs using its proprietary IsoDDE drug design engine. The work will incorporate exclusive, high-quality datasets supplied by MSD for the collaboration.
Isomorphic Labs describes IsoDDE as a therapeutic-modality-agnostic drug design engine based on artificial intelligence foundation models. The company says the system is designed to provide the predictive fidelity needed to explore novel biological systems.
The partnership will focus on identifying candidates made from small molecules, although the announcement does not name the oncology target or disclose the compounds under investigation.
MSD will lead development and commercialization
MSD will be responsible for preclinical and clinical development, manufacturing and commercialization of any product that emerges from the collaboration. The arrangement therefore assigns the computational design work to Isomorphic Labs while MSD takes responsibility for advancing potential products through development.
According to the agreement’s terms, Isomorphic Labs will receive an upfront payment from MSD. It may also receive additional payments tied to research, development, regulatory and commercial milestones, along with tiered royalties on net sales.
Isomorphic Labs has the option to co-finance development activities in exchange for higher royalties. The announcement does not provide the value of the upfront payment, the milestone payments or the royalty rates.
Why the collaboration matters
The companies are combining computational modeling with experimental laboratory work and pharmaceutical research. George Addona, MSD Research Laboratories’ senior vice president and head of Discovery, Preclinical Development and Translational Medicine, said the goal is to identify new ways to design and create better candidates more quickly by combining MSD’s internal data and research capabilities with Isomorphic Labs’ modeling and computing capabilities.
Sarah Skerratt, Isomorphic Labs’ research director, said the company will apply its drug design engine to the program and use IsoDDE’s generative and predictive capabilities to address it.
Isomorphic Labs was founded in 2021 and is led by chief executive Sir Demis Hassabis and president Max Jaderberg. The company is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland. MSD, also known as Merck & Co., Inc. in the United States and Canada, will determine whether any resulting candidates progress through development and commercialization. The companies’ announcement does not guarantee regulatory approval or commercial success for products in development.
